EVFM.OIDEvofem Biosciences, INC
10-Q: Evofem Biosciences Reports First Quarter 2024 Results Amidst Merger Reinstatement
Sentiment:
Quarterly Report
Evofem Biosciences reported a net loss of $4.8 million for the first quarter of 2024, with product sales declining to $3.6 million, while also navigating a complex merger agreement with Aditxt.
Capital raiseThe company is dependent on securing additional funding through various means, including equity or debt financing, licensing agreements, or other business combinations.The company is exploring opportunities for non-dilutive financings.The merger agreement with Aditxt includes provisions for future capital raises tied to preferred stock purchases.
Worse than expectedThe company's net loss increased significantly compared to the same period last year.Product sales decreased by 38% year-over-year, indicating a significant drop in revenue.The company's cash and cash equivalents remained at zero, with restricted cash at $0.7 million.The company's ability to continue as a going concern is in doubt.
Summary
- Evofem Biosciences reported a net loss of $4.8 million for the first quarter of 2024, compared to a net loss of $2.4 million in the same period last year.
- Net product sales decreased to $3.6 million, a 38% drop from $5.8 million in the first quarter of 2023, primarily due to the timing of price increases and a cyberattack impacting prescription processing.
- The company's operating expenses totaled $6.4 million, a decrease from $9.4 million in the prior year, driven by reductions in selling and marketing, and general and administrative costs.
- Research and development expenses increased slightly to $0.6 million from $0.5 million in the first quarter of 2023.
- The company's cash and cash equivalents remained at zero, with restricted cash at $0.7 million as of March 31, 2024.
- Evofem is facing a working capital deficit of $67.3 million and an accumulated deficit of $893.6 million.
- The company's ability to continue as a going concern is in doubt, contingent on securing additional funding and increasing revenue.
- The merger agreement with Aditxt was initially terminated but subsequently reinstated with amendments, including a $1 million payment to Evofem and future capital raises tied to preferred stock purchases.
Sentiment
Score: 3
Explanation: The document indicates significant financial challenges, including a substantial net loss, declining sales, and a going concern warning. While there are some positive developments, such as cost reductions and the reinstatement of the merger agreement, the overall sentiment is negative due to the company's precarious financial position.
Positives
- Operating expenses decreased by 31% year-over-year, indicating cost-cutting measures.
- The merger agreement with Aditxt was reinstated, providing a potential path forward.
- Evofem received a $1 million payment from Aditxt as part of the reinstated merger agreement.
- The company continues to work on expanding access to Phexxi, including the removal of prior authorization requirements in some states.
Negatives
- Net product sales decreased by 38% year-over-year, indicating a significant drop in revenue.
- The company reported a net loss of $4.8 million for the quarter, a significant increase from the prior year.
- Evofem has a substantial working capital deficit of $67.3 million and an accumulated deficit of $893.6 million.
- The company's ability to continue as a going concern is in doubt, contingent on securing additional funding and increasing revenue.
- The company's cash and cash equivalents remained at zero, with restricted cash at $0.7 million.
Risks
- The company's ability to continue as a going concern is in doubt due to insufficient cash and significant losses.
- The company is dependent on securing additional funding through various means, including equity or debt financing, licensing agreements, or other business combinations.
- Failure to obtain necessary funding could force the company to reduce spending, liquidate assets, or cease operations.
- The company is facing a working capital deficit of $67.3 million and an accumulated deficit of $893.6 million.
- The company's product sales decreased by 38% year-over-year, indicating a significant drop in revenue.
- The company is subject to risks related to the commercialization of Phexxi and its supply chain.
- The company is subject to risks related to the merger agreement with Aditxt, including the possibility of termination.
Future Outlook
The company anticipates it will continue to incur net losses for the foreseeable future and is dependent on securing additional funding through various means, including equity or debt financing, licensing agreements, or other business combinations. The company is working towards closing the merger with Aditxt in the second half of 2024.
Management Comments
- Management believes that the company's cash and cash equivalents as of March 31, 2024 are insufficient to fund operations for at least the next 12 months.
- Management plans to meet the company's cash flow needs by generating revenue from the sale of Phexxi, restructuring current payables, and obtaining additional funding.
- Management has concluded that the uncertainties associated with the company's ability to obtain additional financing raise substantial doubt about the company's ability to continue as a going concern.
Industry Context
The company operates in the competitive women's health market, focusing on non-hormonal contraceptive options. The company's product, Phexxi, is positioned as a unique alternative to hormonal contraceptives, targeting a specific segment of women who prefer non-hormonal options. The company is also exploring opportunities for expansion into new markets and product offerings.
Comparison to Industry Standards
- Evofem's revenue decline contrasts with the broader pharmaceutical industry, where many companies experience steady or increasing sales.
- The company's significant net loss and negative cash flow from operations are concerning compared to industry benchmarks for commercial-stage biopharmaceutical companies.
- The company's reliance on external funding and the uncertainty surrounding its going concern status are atypical for companies with a commercialized product.
- The company's operating expense reductions are a positive step, but they need to be coupled with revenue growth to achieve sustainability.
- The reinstatement of the merger agreement with Aditxt is a positive development, but the company's financial position remains precarious.
Stakeholder Impact
- Shareholders face significant risk due to the company's financial instability and going concern warning.
- Employees may be affected by potential cost reductions or restructuring.
- Customers may experience disruptions in product availability or support.
- Suppliers may face extended payment terms or potential defaults.
- Creditors face increased risk of non-payment due to the company's financial challenges.
Next Steps
- The company will continue to focus on top-line growth and maintain a lean operating structure.
- The company will explore opportunities for organic growth, entry into new markets, and expansion of its product offering beyond Phexxi.
- The company will work towards closing the merger with Aditxt in the second half of 2024.
- The company will seek additional funding through various means, including equity or debt financing, licensing agreements, or other business combinations.
Key Dates
| Date | Description |
|---|---|
| 2014-06-11 | Date of common warrants issuance. |
| 2018-05-24 | Date of common warrants issuance. |
| 2019-04-11 | Date of common warrants issuance. |
| 2019-06-10 | Date of common warrants issuance. |
| 2019-12-31 | Date of lease contract term. |
| 2020-04-14 | Date of first amendment to the 2020 lease. |
| 2020-04-22 | Date of Baker Bros Notes issuance. |
| 2020-04-23 | Date of Baker Bros Notes issuance. |
| 2020-04-24 | Date of Baker Bros Notes issuance and common warrants issuance. |
| 2020-04-30 | Date of Baker Bros Purchase Agreement. |
| 2020-06-09 | Date of Baker Bros Notes issuance and common warrants issuance. |
| 2020-10-14 | Date of Adjuvant Notes issuance. |
| 2021-01-01 | Date of Rush License Agreement. |
| 2021-11-20 | Date of First Baker Amendment. |
| 2021-12-15 | Date of Series E1 Convertible Preferred Stock issuance. |
| 2022-01-13 | Date of common warrants issuance. |
| 2022-03-01 | Date of common warrants issuance. |
| 2022-03-21 | Date of Second Baker Amendment. |
| 2022-04-04 | Date of Adjuvant Amendment. |
| 2022-05-04 | Date of common warrants issuance. |
| 2022-05-24 | Date of common warrants issuance. |
| 2022-05-27 | Date of sublease agreement with AMN Healthcare, Inc. |
| 2022-05-31 | Date of Underwritten Public Offering and June 2022 Baker Warrants issuance. |
| 2022-06-28 | Date of common warrants issuance. |
| 2022-06-30 | Date of June 2022 Baker Warrants issuance. |
| 2022-09-14 | Date of Adjuvant Notes amendment. |
| 2022-09-15 | Date of Third Baker Amendment and Adjuvant Forbearance Agreement. |
| 2022-09-30 | Date of December 2022 Notes issuance. |
| 2022-10-03 | Date of OTCQB listing. |
| 2022-12-16 | Date of Series D Non-Convertible Preferred Stock issuance. |
| 2022-12-19 | Date of Secured Creditor Forbearance Agreement. |
| 2022-12-21 | Date of common warrants issuance and Series F-1 Shares issuance. |
| 2023-02-17 | Date of common warrants issuance. |
| 2023-02-28 | Date of Placement Agent Agreement. |
| 2023-03-07 | Date of Notice of Event of Default and Reservation of Rights. |
| 2023-03-20 | Date of common warrants issuance. |
| 2023-04-05 | Date of common warrants issuance. |
| 2023-06-01 | Date of sublease agreement termination. |
| 2023-06-30 | Date of June 2022 Baker Warrants issuance. |
| 2023-07-03 | Date of common warrants issuance. |
| 2023-08-04 | Date of common warrants issuance. |
| 2023-08-07 | Date of Series E-1 Convertible Preferred Stock issuance. |
| 2023-09-08 | Date of Fourth Baker Amendment. |
| 2023-09-27 | Date of common warrants issuance and Prefunded Common Warrants issuance. |
| 2023-10-01 | Date of $1.0 million upfront payment to Baker Purchasers. |
| 2023-12-11 | Date of Merger Agreement with Aditxt, Inc. |
| 2023-12-21 | Date of Series F-1 Convertible Preferred Stock issuance. |
| 2024-01-01 | Date of Washington State Health Care Authority (HCA) removed the Prior Authorization requirement for Phexxi. |
| 2024-02-26 | Date of Baker Notes re-assignment. |
| 2024-03-26 | Date of USPTO Notice of Allowance for patent application 17/823,020. |
| 2024-03-31 | End of the first quarter of 2024. |
| 2024-04-19 | Date of conversion price reset. |
| 2024-04-26 | Date of termination notice to Aditxt. |
| 2024-05-02 | Date of Reinstatement and Fourth Amendment to the Merger Agreement. |
| 2024-05-10 | Date of common stock outstanding. |
| 2024-06-17 | Date of Parent Capital Raise. |
| 2024-07-01 | Date of Parent Capital Raise. |
Keywords
Evofem Biosciences, Phexxi, Contraceptive, Merger, Aditxt, Financial Results, Net Loss, Product Sales, Operating Expenses, Going Concern, Debt, Capital Raise
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.